Literature DB >> 10752527

Inhibition of neutrophil superoxide production by uremic concentrations of guanidino compounds.

Aki Hirayama1, Alberto A Noronha-Dutra1, Michael P Gordge1, Guy H Neild1, John S Hothersall1.   

Abstract

In uremia, diminished reactive oxygen intermediate production is an important consequence of impaired neutrophil function. The effects of guanidino compounds, which are known uremic toxins, on neutrophil reactive oxygen intermediate production in vitro were studied. Neutrophils from healthy volunteers were exposed for 3 h to individual guanidino compounds or mixed guanidino compounds (GCmix), at concentrations observed in uremic plasma. After removal of the guanidino compounds, the neutrophils were activated by adhesion, N-formylmethionylleucylphenylalanine, phorbol myristate acetate, or opsonized zymosan, and superoxide production was measured by monitoring lucigenin chemiluminescence. The direct effects of guanidino compounds on superoxide production in activated neutrophils were also measured. The energy status (ATP and creatine phosphate), antioxidant status (total glutathione), and glycolytic flux (lactate production) were measured. GCmix pretreatment decreased superoxide production in activated neutrophils (activated by N-formylmethionylleucylphenylalanine or zymosan) by 50% (P < 0.01), decreased ATP concentrations by 60% (P < 0.05), and inhibited glycolytic flux (lactate production) by 45% (P < 0.01) but did not alter glutathione concentrations. Simultaneous GCmix exposure and activation did not inhibit NADPH oxidase activity in cell lysates but inhibited superoxide formation in zymosan-activated intact neutrophils; this inhibition was reversed after removal of the guanidino compounds. Guanidinosuccinic acid, guanidinopropionic acid, and guanidinobutyric acid, when tested individually, were each as potent as GCmix. The inhibition of neutrophil superoxide generation by guanidino compounds results from decreased energy status. Micromolar concentrations of guanidino compounds significantly inhibit neutrophil metabolism, with serious implications for the functions of neutrophils in host defenses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752527     DOI: 10.1681/ASN.V114684

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease.

Authors:  Chetan V Jawale; Kritika Ramani; De-Dong Li; Bianca M Coleman; Rohan S Oberoi; Saran Kupul; Li Lin; Jigar V Desai; Greg M Delgoffe; Michail S Lionakis; Filitsa H Bender; Alexander J Prokopienko; Thomas D Nolin; Sarah L Gaffen; Partha S Biswas
Journal:  Sci Transl Med       Date:  2020-06-17       Impact factor: 17.956

2.  Expression of CD18 on the neutrophils of patients with diabetic retinopathy.

Authors:  Huping Song; Lili Wang; Yannian Hui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07-18       Impact factor: 3.117

Review 3.  Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells.

Authors:  Maxime Espi; Laetitia Koppe; Denis Fouque; Olivier Thaunat
Journal:  Toxins (Basel)       Date:  2020-05-06       Impact factor: 4.546

Review 4.  Myeloid leukocytes' diverse effects on cardiovascular and systemic inflammation in chronic kidney disease.

Authors:  Alexander Hof; Simon Geißen; Kezia Singgih; Martin Mollenhauer; Holger Winkels; Thomas Benzing; Stephan Baldus; Friedrich Felix Hoyer
Journal:  Basic Res Cardiol       Date:  2022-07-27       Impact factor: 12.416

Review 5.  Immune dysfunction in uremia&#8212;an update.

Authors:  Gerald Cohen; Walter H Hörl
Journal:  Toxins (Basel)       Date:  2012-10-24       Impact factor: 4.546

Review 6.  The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review.

Authors:  Inge Oudman; Joseph F Clark; Lizzy M Brewster
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.